Cargando…
External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme
Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods for TMB testing have not yet been standardized. The International Quality Network for Pathology (IQNPath) organized a pilot external quality assessment (EQA) scheme fo...
Autores principales: | Esposito Abate, Riziero, Cheetham, Melanie H., Fairley, Jennifer A., Pasquale, Raffaella, Sacco, Alessandra, Nicola, Wolstenholme, Deans, Zandra C., Patton, Simon J., Normanno, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931778/ https://www.ncbi.nlm.nih.gov/pubmed/36355212 http://dx.doi.org/10.1007/s00428-022-03444-y |
Ejemplares similares
-
Correction to: External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme
por: Esposito Abate, Riziero, et al.
Publicado: (2022) -
Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
por: Deans, Zandra C., et al.
Publicado: (2017) -
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)
por: Fenizia, Francesca, et al.
Publicado: (2021) -
IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing
por: Deans, Zandra C., et al.
Publicado: (2019) -
International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA
por: Keppens, Cleo, et al.
Publicado: (2018)